Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 11:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Subcutaneous Fat Disorder Clear all
Completed Phase 2 Interventional Results available

Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

NCT01592240
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
PBO, 200mg PF-04950615 (RN316), 300mg PF-04950615 (RN316), PF-04950615
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
74
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoolSculpting of the Flank With Alternate Treatment Parameters

NCT02081196
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq CoolSculpting System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Sacramento, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional

Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)

NCT02907411
View directory record Official record
Conditions
Lipedema
Interventions
Quadrivas Therapy
Other
Lead sponsor
University of Arizona
Other
Eligibility
19 Years to 70 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 3, 2026, 11:38 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

The Early and Late Contribution of Fasting and Postprandial Triglycerides on Newborn Subcutaneous and Intrahepatic Fat in Pregnancy

NCT04394806
View directory record Official record
Conditions
Pregnancy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
0 Years to 39 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Technical Validation of Lunar iDXA (GE Healthcare) Visceral Fat Tool

NCT00987298
View directory record Official record
Conditions
Obesity
Interventions
Visceral fat mass measurement
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 90 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 7, 2010 · Synced Sep 3, 2026, 11:38 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Testing the Adipose Expandability Hypothesis In Vivo During Overfeeding

NCT04583514
View directory record Official record
Conditions
Overweight and Obesity, Metabolic Syndrome
Interventions
Control, Overfeeding
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 42 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD8233 After Multiple Dose Administration in Subjects With Dyslipidemia

NCT04155645
View directory record Official record
Conditions
Dyslipidemia
Interventions
AZD8233 subcutaneous injection, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Chula Vista, California • Glendale, California • La Mesa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 3, 2026, 11:38 AM EDT
Completed No phase listed Observational

Adipose Cellular Kinetics of Lipedema

NCT05394467
View directory record Official record
Conditions
Lipedema
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
17 participants
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

"Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat

NCT00377975
View directory record Official record
Conditions
Obesity
Interventions
Ephedrine, Pioglitazone, Caffeine
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

NCT01435382
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
Interventions
PF-04950615 (RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
7
States / cities
Chula Vista, California • Miami, Florida • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2018 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study

NCT01032889
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • Beverly Hills, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

NCT01542034
View directory record Official record
Conditions
Moderate or Severe Submental Fullness
Interventions
Deoxycholic acid injection, Placebo
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
506 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
31
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study on the Submental Area

NCT01859091
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Sep 3, 2026, 11:38 AM EDT
Completed No phase listed Observational

Assessment of Insulin Resistance, NAFLD, Predictors of CV Morbidity, and Subcutaneous Adipose and Visceral Adipose Gene Expression in Patients Undergoing Gastric Bypass Surgery

NCT01007955
View directory record Official record
Conditions
Morbid Obesity, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Sep 3, 2026, 11:38 AM EDT
Recruiting Phase 4 Interventional

Clinical Trial in Patients With Barth Syndrome- 4TAZPower

NCT07531251
View directory record Official record
Conditions
Barth Syndrome
Interventions
Elamipretide, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
5 Years to 55 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Needham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Injection Site Tolerability, Safety, Pharmacokinetics, Pharmacodynamics in Different Single-Dose Treatments of Alirocumab SAR236553 (REGN727) in Healthy Subjects

NCT01443650
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
alirocumab SAR236553 (REGN727)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 27, 2013 · Synced Sep 3, 2026, 11:38 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Insight Into Subcutaneous Adipose Tissue Disorders

NCT02838277
View directory record Official record
Conditions
Lipedema, Dercum's Disease, Familial Multiple Lipomatosis, Madelung's Disease
Interventions
Not listed
Lead sponsor
University of Arizona
Other
Eligibility
19 Years to 70 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

NCT02043301
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Bococizumab (PF-04950615; RN316)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Anaheim, California • South Miami, Florida • Overland Park, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diet Induced Weight Loss to Reduce Inflammation in Obese Women

NCT01699906
View directory record Official record
Conditions
Obesity
Interventions
Diet regimen to induce weight loss
Other
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Not applicable Interventional

Use of MCT Oil for Enhancement of Weight Loss in Obese Patients

NCT00207272
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
1170-1870 kcal/day liquid diet, Gastric bypass surgery, Biopsy.visceral adipose tissue, Biopsy.omental adipose tissue, Biopsy. subcutaneous abdominal adipose tissue, Blood sample
Behavioral · Procedure
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2008 · Synced Sep 3, 2026, 11:38 AM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging of the Face and Bones

NCT00001762
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 3, 2026, 11:38 AM EDT
Completed Phase 4 Interventional Results available

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

NCT04126603
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebos
Drug
Lead sponsor
Sabyasachi Sen
Other
Eligibility
20 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 3, 2026, 11:38 AM EDT